Analyst positive on 2009 health care investing; Teva gets new partner;

> Although many drug companies claim their medications are made in the United States, many of the ingredients are in fact made elsewhere, and quality control is becoming an increasing concern. Report

> A JP Morgan analyst has some encouraging news for health care investing in 2009. Report

> Teva Pharmaceutical Industries and partnered with Lonza Group to develop, manufacture and market a portfolio of generic equivalents of selected biologic pharmaceuticals. Release

> Belgian biotech Cardio3 BioSciences has rounded up €13.7 million from venture groups and grants. Report

> The annual JP Morgan conference in San Francisco helped underscore the dramatically different futures that face big pharma and biotech compared with the small developers operating in the field. Report

> San Diego-based Metabasis Therapeutics has joined the ranks of the restructuring. The company says it will reduce its workforce by about 43 percent, or 38 employees. Report

> Abraxis BioScience is spinning off Abraxis Health, creating a standalone company that will operate in the personalized medicine arena. Report

> Pfizer has run into a roadblock at the FDA in its longrunning quest to gain an approval for its experimental osteoporosis drug Fablyn. The pharma giant says the FDA has asked for more information on the drug. Report

> Back in the late 1990s, Harvard researcher Steven Shoelson stumbled on to some old evidence that the drug salsalate may be a cheap and effective therapy to use against diabetes. An article published in a German medical journal in 1876 suggested that the therapy could help control blood sugar. And since then Shoelson and researchers at the Joslin Diabetes Center have produced positive data in small trials involving Type 2 diabetes. Article

> ReNeuron has received a green light from British regulators to proceed with a clinical trial of its stem cell therapy for stroke damage. Report

And Finally... A new review from the Cochrane Library again finds that studies with positive findings are more likely to end up in print than studies with negative findings are. While 73 percent of positive studies get published, only 41 percent of studies that sow a drug of treatment as bad effects or no effect at all, end up in print. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.